CIK 0001802665 · Large accelerated filer
Harmony Biosciences Holdings, Inc.
Sign in to watch- Ticker
- HRMY
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 822279923
- Phone
- (484) 539-9800
- Business address
- 630 W GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING, PA, 19462
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $3,108,586
- in 2 filings
Net −$3,108,586. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 87 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-01-24 | Dayno Jeffrey M. PRESIDENT, CEO | Option exercise | +10,500 | 10,500 | ||
| 2026-01-24 | Dayno Jeffrey M. PRESIDENT, CEO | Shares withheld for taxes | −4,785 | $36.82 | $176K | 5,715 |
| 2026-01-24 | Dayno Jeffrey M. PRESIDENT, CEO | Option exercise · Restricted Stock Units | −10,500 | 21,000 | ||
| 2026-01-22 | Zaeske Adam H. CHIEF COMMERCIAL OFFICER | Grant or award · Stock Option | +56,900 | 56,900 | ||
| 2026-01-22 | Zaeske Adam H. CHIEF COMMERCIAL OFFICER | Grant or award · Restricted Stock Units | +16,200 | 16,200 | ||
| 2026-01-22 | Budur Kumar CHIEF MEDICAL OFFICER | Grant or award · Stock Option | +42,600 | 42,600 | ||
| 2026-01-22 | Budur Kumar CHIEF MEDICAL OFFICER | Grant or award · Restricted Stock Units | +12,200 | 12,200 | ||
| 2026-01-22 | Serafin Andrew CHIEF STRATEGY OFFICER | Grant or award · Stock Option | +42,600 | 42,600 | ||
| 2026-01-22 | Serafin Andrew CHIEF STRATEGY OFFICER | Grant or award · Restricted Stock Units | +12,200 | 12,200 | ||
| 2026-01-22 | Kapadia Sandip CHIEF FINANCIAL OFFICER | Grant or award · Stock Option | +42,600 | 42,600 | ||
| 2026-01-22 | Kapadia Sandip CHIEF FINANCIAL OFFICER | Grant or award · Restricted Stock Units | +12,200 | 12,200 | ||
| 2026-01-22 | Dayno Jeffrey M. PRESIDENT, CEO | Grant or award · Stock Option | +184,600 | 184,600 | ||
| 2026-01-22 | Dayno Jeffrey M. PRESIDENT, CEO | Grant or award · Restricted Stock Units | +52,900 | 52,900 | ||
| 2026-01-15 | Kapadia Sandip CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −20,961 | $35.92 | $753K | 0 |
| 2025-12-12 | Dayno Jeffrey M. PRESIDENT, CEO | Option exercise 10b5-1 | +20,000 | $8.22 | $164K | 20,000 |
| 2025-12-12 | Dayno Jeffrey M. PRESIDENT, CEO | Sale 10b5-1 | −20,000 | $40.11 | $802K | 0 |
| 2025-12-12 | Dayno Jeffrey M. PRESIDENT, CEO | Sale 10b5-1 | −5,933 | $40.11 | $238K | 0 |
| 2025-12-12 | Dayno Jeffrey M. PRESIDENT, CEO | Option exercise · Stock Option 10b5-1 | −20,000 | 0 | ||
| 2025-12-05 | Kapadia Sandip CHIEF FINANCIAL OFFICER | Option exercise 10b5-1 | +20,000 | $29.03 | $581K | 20,000 |
| 2025-12-05 | Kapadia Sandip CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −20,000 | $39.54 | $791K | 0 |
Page 4 of 14 · 268 trades